We studied the pharmacokinetic (PK) profile of single daily dose i.v. BU in children who underwent reducedintensity conditioning (RIC) transplantation. A cohort of 19 patients p4 years of age (group 1) and 33 patients 44 years (group 2) was studied. Patients received a BU test dose for PK studies, followed by two treatment doses adjusted to target an area under the curve (AUC) of 4000 lM min per day. Patients in group 1 attained a lower AUC as compared to group 2 (3568 vs 4035 lM min). In group 1, 67% patients and in group 2, 84% patients achieved AUC within the targeted range. Stable donor chimerism was achieved in 56% patients in group 1 and 79% in group 2. Eight patients required a second transplantation because of graft failure. Because of the concern that a low AUC adversely affected outcomes, a second cohort of 23 patients followed a modified protocol with a targeted AUC of 5000 lM min. A higher AUC was attained (4825 lM min). Stable donor chimerism was achieved in 91% of patients. Our results show that RIC regimens using two single daily doses of i.v. BU are effective in children, but a targeted AUC of 5000 lM min is recommended.
Introduction
BU is a bifunctional DNA-alkylating agent used extensively in conditioning regimens before allogeneic SCT. 1, 2 BU has a 'narrow' therapeutic index when used as a conditioning agent, especially after oral administration, and systemic exposure to the drug is highly variable after administration to patients. Excessive BU exposure could lead to increased transplant-related toxicities such as hepatic veno-occlusive disease (VOD), whereas inadequate exposure could result in graft failure. [3] [4] [5] [6] Because of the correlation between BU systemic exposure and its effects, therapeutic drug monitoring in hematopoietic stem and progenitor cell (HSPC) transplantation has been recommended. 7 BU was previously available for only oral administration, and erratic absorption of the drug contributed to unpredictable blood levels and variable therapeutic and side effects. [8] [9] [10] The availability of an i.v. formulation of BU has removed some uncertainties associated with its adsorption, but variability in its pharmacokinetic (PK) profile remains significant. 11, 12 Monitoring of systemic exposure in patients after i.v. BU administration is deemed necessary. 13 The use of i.v. BU has initially followed the original dosing schedule for oral administration, which was four times daily for 4 days. 14, 15 More recently, once daily dosing of i.v. BU has been shown to be a convenient and effective alternative. [16] [17] [18] [19] [20] [21] A better understanding of the PK profile of i.v. BU when administered as a single daily dose will facilitate its use.
The PK profile of BU is known to be different between children and adults. Children appear to have a higher BU clearance, thus resulting in lower systemic exposure. [22] [23] [24] [25] It was proposed that the higher glutathione S-transferase activity in children might explain the difference. 26 Alternatively, the underlying diseases in children might contribute to the observed variation. [27] [28] [29] Among children, there is also an age-dependent difference between the younger and older patients, resulting in variability in BU exposure after a standard, weight-normalized dose. 8, 30 Various targeted dosing strategies have been proposed to compensate for the age-dependent difference in BU PK profile. [31] [32] [33] [34] [35] In the past several years, the Children's Memorial Hospital SCT program has used reduced-intensity conditioning (RIC) regimens to prepare pediatric patients with malignant and nonmalignant diseases for HSPC transplantation. [36] [37] [38] The backbone of these regimens is comprised of i.v. BU and fludarabine, with or without antithymocyte globulin or extracorporeal photophoresis (ECP). The administration of BU is only for 2 days and the total BU exposure in our patients is estimated to be about half of that in patients who undergo myeloablative transplantation using BU-containing regimens. We hypothesized that the lowered BU exposure in our patients will decrease regimenrelated toxicity but not compromise efficacy.
For the administration of i.v. BU, we have recently adopted the once daily dosing approach. [16] [17] [18] [19] Because only two single daily doses of i.v. BU were to be given in our RIC regimens, it was not possible to perform therapeutic drug monitoring and real-time dose adjustment after actual treatment has started. We used an alternative strategy, in which a test dose was given several days before the treatment dose to obtain the BU PK profile for each patient. The PK results were then used to determine the treatment dose that each patient required. It was hoped that the test dose PK approach would help optimize BU exposure in each patient, thereby improving outcome.
We have previously found the RIC regimens to be well tolerated by our patients and the clinical results comparable to those after conventional regimens. [36] [37] [38] We have also demonstrated that the test dose PK approach was useful in allowing treatment dose adjustments to be made to achieve a desired area under the curve (AUC) exposure. 17 In the current study, we expanded our PK analysis to include more patients and attempted to answer two specific questions: how effective is the PK-based, individualized dosing protocol in bringing BU exposure to within a targeted range, and what are the appropriate values for this targeted range in children who are to receive RIC regimens before HSPC transplantation?
Patients and methods

Patients
Between July 2003 and May 2008, pediatric patients with high-risk malignancies or nonmalignant conditions, who underwent allogeneic HSPC transplantation after receiving single daily dose i.v. BU conditioning, were included in this study. These patients were part of three RIC protocols described below. All patients were required to have their primary diagnosis confirmed by histology and/or laboratory tests. Signed informed consents by parents to participate in the protocols and the use of their records for research were obtained in compliance with the institutional review board. Assents of patients were also obtained when applicable. BU PK samples were prospectively collected and analyzed. The clinical outcomes were retrospectively analyzed by review of medical charts.
Treatment regimens
Patients were enrolled on three RIC transplant protocols. [36] [37] [38] The conditioning regimen in the first protocol (Flu/BU/ATG) included the following agents: an i.v. BU test dose (0.8 mg/kg) given over 2 or 3 h on day À10; Flu 30 mg/m 2 per day for 6 days (days À10 to À5); a single daily treatment dose of i.v. BU given over 3 h every day for 2 days (days À5 and À4), with individualized dosing based on the test dose PK results; and rabbit ATG (2 mg/kg per day) or equine ATG (40 mg/kg per day) for 4 days (days À4, À3, À2 and À1). Allogeneic HSPC were infused on day 0. In the second protocol (Flu/BU/ECP), instead of ATG, patients received four ECP treatments in the 2 weeks before the transplantation, and 12 treatments in the 100 days after. The third protocol (Flu/BU) used Flu and i.v. BU only, without ATG or ECP. Between 2003 and 2006, all patients were enrolled in the first protocol. Between 2006 and 2008, patients with nonmalignant diseases continue to be enrolled in the first protocol, whereas patients with malignant disease were enrolled in the second protocol if they were over 20 kg and in the third protocol if they were under 20 kg.
BU PK analysis
On day À10, blood samples for PK analysis were collected at 3, 3.5, 5 and 7 h after the start of the infusion of the i.v. BU test dose. On day À5, samples were collected at 3, 3.5, 5, 8 and 24 h after the start of the infusion of the first treatment dose. Samples were placed on wet ice after blood collection and processed within 1 h after collection. Plasma was separated by centrifugation and then stored at À20 1C until the complete set of blood samples for each dose was obtained and shipped to The Seattle Cancer Care Alliance Clinical Pharmacokinetics Laboratory for PK analysis. For administrative reasons, PK samples for two patients were assayed at the University of Pennsylvania pharmacology laboratory by a similar assay.
Plasma BU level was determined by gas chromatography-mass spectrometry. BU PK values were calculated by fitting a bi-exponential equation. AUC was calculated by trapezoidal approximation and extrapolation based on computer-generated parameters from zero to infinity. The clearance was calculated using the weight-normalized BU dose divided by the measured AUC. On the basis of the test dose AUC achieved, the single daily i.v. BU treatment dose was calculated using the following formula: Treatment dose to be given in mg ¼ 4000 mM min Â (Test dose given in mg/ Test dose AUC achieved in mM min). As written, the formula targeted a treatment dose AUC of 4000 mM min (range 3200-4800). In a later cohort of patients, the formula was modified to target a higher treatment dose AUC of 5000 mM min (range 4200-5800).
To compare the actual AUC achieved in patients with the AUC predicted from PK models, we derived the following parameters: (1) Expected test dose AUC ¼ Test dose in mg Â (1000 mM min/(0.8 mg/kg Â body weight in kg)) and (2) Expected treatment dose AUC ¼ Treatment dose in mg Â (Test dose AUC in mM min/Test dose in mg). The first parameter is based on the assumption that a standard dose of 0.8 mg/kg yields an AUC of 1000 mM min, 39 and the second, on the assumption of dose linearity in the PK profile. Deviation of the actual AUC from the expected AUC will reflect inter-and intrapatient variability in systemic exposure or nonlinearity in the PK profile of the drug.
Supportive care
For most patients, the conditioning regimen and transplantation was performed in the outpatient setting, with patients following standard protocols for infection precaution. For anticonvulsion prophylaxis, lorazepam (0.05 mg/kg) was given i.v. once before each dose of i.v. BU. Patients received i.v. immunoglobulin (250 mg/kg) on day À1 and continuing each week until day þ 100, and then monthly up to 6 months post transplant or until they were able to sustain their immunoglobulin level without support. Fluconazole, 3-5 mg/kg per day, was started with the conditioning therapy on day À10 and continued until day þ 100. Acyclovir, 250 mg/m 2 , was administered every 12 h beginning on day À5 and continued until day þ 100. Pentamidine, 4 mg/kg, was administered i.v. on day À1 and then every 30 days up to 6 months post transplant. Screening for CMV reactivation was pursued weekly in patients at risk with a viral DNA quantitative PCR assay (ViraCor Laboratories). If 41000 copies per ml or a rising number of copies were detected, preemptive therapy was initiated with ganciclovir at 5 mg/kg every 12 h for 5-7 days and then at 5 mg/kg per dose daily. For prophylaxis against GVHD, all patients received CsA and mycophenylate mofetil.
Engraftment and chimerism analysis
After transplant, donor cell engraftment was assessed by blood counts and chimerism studies. Donor chimerism studies were performed when a patient's post-nadir blood counts recovered and continued weekly until donor chimerism was stable. Donor chimerism was assessed using a PCR-based variable number tandem repeat (VNTR) analysis of peripheral blood leukocytes. 40 Polymorphic gene loci used in the VNTR analysis were APO-B, D1S80, D1S111, D17S30, TDG/ZP3, YNZ22 and AMG. The sensitivity for the detection of donor and recipient chimerism was 5 and 1%, respectively. Donor chimerism in five patients was analyzed by the short tandem repeat methodology because of a lack of informative VNTR loci.
Statistical analysis
Statistical analysis of the data was performed using the R statistical software package (R Foundation for Statistical Computing). Comparison of values between patient groups was performed using Student's t-, w 2 -and KolmogorovSmirnov statistical tests. Regression analysis was performed using the linear model fitting function. Survival curves were produced using the product limit method of Kaplan-Meier.
Results
Patients
A total of 52 pediatric patients transplanted between July 2003 and May 2008 using RIC regimens were included in the initial analysis. Data for 30 of these patients have been described in part in a previous report. 17 To allow for analysis of the effect of age on BU PK, as suggested in previous reports, 30 ,39 the patients were divided into two groups: group 1 includes patients r4 years of age (n ¼ 19) and group 2 included patients 44 years (n ¼ 33) ( Table 1) . The patient characteristics in the two groups were different. The median age of patients in groups 1 and 2 was 0.58 and 11.49 years, respectively. The median body weight in groups 1 and 2 was 7.8 and 42.5 kg, respectively. There were more males than females in group 1 but the malefemale ratio was equal in group 2. In group 1, 89% had nonmalignant diseases (immunodeficiency, 13; metabolic disease, 2; marrow failure, 1; histiocytosis, 1) and 11% had malignant diseases (ALL, 1; lymphoma, 1); in group 2, 18% had nonmalignant diseases (immunodeficiency, 1; marrow failure, 5) and 82% had malignant diseases (ALL, 8; AML, 5; CML, 4; myelodysplastic syndrome (MDS), 2; lymphoma, 4; neuroblastoma, 4). In group 1, all patients followed the Flu/BU/ATG protocol; in group 2, 49, 36 and 15% followed the Flu/BU/ATG, Flu/BU/ECP and Flu/BU protocols, respectively. In group 1, 42% and in group 2, 55% received stem cells from related donors, with the rest receiving stem cells from unrelated donors. In group 1, 58 and 42% and in group 2, 94 and 6% received donor PBSC and umbilical cord blood (UCB), respectively; no patient in this cohort received donor BM.
PK of BU test dose
Pharmacokinetic studies were performed on all patients after administration of a test dose of i.v. BU at 0.8 mg/kg 5 days before the first treatment dose. Three patients in group 1 and three in group 2 were excluded from the analysis because of incorrect procurement of PK samples. A total of 46 patients yielded informative results. After the test dose, PK analysis showed a median AUC was 886 mM min in group 1 (range 439-1828) and 965 mM min in group 2 (range 579-1970) ( Table 2) . We compared the distribution of the actual test dose AUC measured with that of the expected AUC, based on the assumption that a test dose of 0.8 mg/kg was expected to give an AUC of 1000 mM min (range 800-1200). 39 The actual test dose AUC achieved in patients showed a significant dispersion in distribution, indicating large interpatient variability in BU exposure after a standard dose ( Figure 1a ). Only 59% of the patients (27 of 46) had an AUC within the desired range of 800 and 1200 mM min. Twenty percent of the patients (9 of 46) had an AUC below this range, and 21% (10 of 46), above. Plotting of the test dose AUC distribution against body weight showed a linear relationship, indicative of a lower BU exposure in the younger patients after the standard test dose (Figure 1b ; regression line: AUC ¼ 834 mM min þ 4.1 Â weight in kg, P ¼ 0.006).
To compensate for the PK variability in patients, we followed an individualized dose-adjustment protocol as outlined in the Patients and method section. Three patients in group 1 and three in group 2 received a standard treatment dose of 3.2 mg/kg because no test dose PK data were available. The remaining 46 patients received individualized treatment doses according to the doseadjustment protocol. The median daily treatment dose given was 3.45 mg/kg in group 1 and 3.20 mg/kg in group 2 ( Table 2 ). The range of the adjusted treatment dose given was wide, varying from 0.8 to 7.2 mg/kg in group 1 and from 0.9 to 5.4 in group 2, indicating that in most patients, the PK-based individualized treatment doses deviated substantially from the standard daily dose of 3.2 mg/kg. In group 1, 10 (53%) and 4 (21%) patients received a dose that was higher or lower than the standard dose, respectively; in group 2, 12 (36%) and 15 (46%) patients received a higher and a lower dose, respectively (Table 3) . Plotting of the weight-normalized treatment dose against the body weight of the patient showed an inverse correlation, with the younger patients requiring a higher treatment dose and the older patients a lower dose (Figure 1c ; regression line: treatment dose given ¼ 4.0 mg/ kgÀ0.01 Â weight in kg, P ¼ 0.001).
PK of BU treatment dose
To evaluate whether the dose-adjustment protocol could bring the treatment dose AUC to within the targeted range, PK assays were performed after the first treatment dose. No useful information was obtained for six patients because of errors in sample procurement or processing. PK results were obtained for the remaining 46 patients. The median treatment dose AUC observed was 3568 mM min in group 1 (range 1511-7254) and 4035 mM min in group 2 (range 2032-5489) ( Table 2 ). The observed treatment dose AUC was plotted against the expected treatment dose AUC as calculated in the dose-adjustment protocol (Figure 2a) . The dispersion in the distribution of the observed treatment dose AUC was reduced, indicating that a decrease in variability of BU exposure after the dose adjustment. Sixtyseven percent (12 of 18) of patients in group 1 and 84% (26 of 31) in group 2 achieved AUC that was within the targeted range of 3200-4800 mM min (Table 3) . Pair-wise comparison of the test dose and treatment dose AUC for each patient showed that the dose-adjustment protocol was effective in bringing the treatment dose AUC to within the targeted range in group 2, but less so in group 1 ( Figure 2b) .
As in the case of the test dose, plotting of the treatment dose AUC achieved showed a linear correlation with body weight, with a lower AUC achieved in the younger patients (Figure 2c ; regression line: AUC ¼ 3665 mM min þ 10.8 Â weight in kg). A nonparametric Kolmogorov-Smirnov test, which measured differences in distributions between sample populations, indicated a statistically significant difference in AUC distributions between groups 1 and 2 (P ¼ 0.001). These results indicated that the dose-adjustment protocol has successfully compensated for the interperson variability in BU exposure, but the younger patients tended to have a lower systemic exposure even after the dose adjustment.
The clearance of BU is inversely proportional to the AUC attained and can be calculated from the PK data. After the test dose, the median BU clearance was 3.70 and 3.25 ml/min per kg for group 1 and group 2, respectively; after the treatment dose, the median BU clearance was 3.75 and 3.13 ml/min per kg, respectively ( Table 2 ). Plotting of the BU clearance against body weight shows an inverse correlation after the test dose (Figure 3a ; regression line: 3.99 ml/min per kgÀ0.013 Â weight in kg, P ¼ 0.008; two outliers were excluded from analyses) or the treatment dose (Figure 3b ; regression line: 4.10 ml/min per kgÀ0.019 Â weight in kg, Po0.001). The estimated BU clearance was 4 ml/min per kg for patients below 20 kg, 3.5 for those between 20 and 40 kg and 3 for those over 40 kg.
Comparison between the BU clearance obtained for each patient after the test dose and that after the treatment dose revealed a good correlation (Figure 3c ).
Regimen-related toxicities and side effects
The conditioning regimens and transplantation were well tolerated by most patients. Of 52, 9 patients (17%) experienced mild to moderate nausea and vomiting. No patient developed severe mucositis, seizure or VOD. Eighteen patients (35%) developed acute GVHD grades 1-2 and six patients (12%) GVHD grade 3. Six patients (10%) developed chronic GVHD (three limited and three extensive). There was no correlation between the rate of regimen-related toxicities and the treatment AUC achieved in these patients.
Engraftment and chimerism analysis
Post transplant donor cell engraftment was assessed by serial donor chimerism measurements. In group 1, one patient died in the first week from complications related to the underlying disease and was excluded from the engraftment analysis. Overall, 71% (36 of 51) of patients achieved engraftment with stable donor chimerism 490% within a median of 25 days after transplantation (range 8-714). The donor engraftment rates differed between groups 1 and 2. In group 1, 10 of 18 patients (56%) achieved stable donor chimerism 490% within a median of 34 days (range 11-714); 3 patients (17%) failed to engraft, with donor chimerism never reaching 10%; 4 patients (22%) had secondary graft failure after donor chimerism had reached 44-77% and 1 patient (5%) has stable mixed chimerism at 20% after a peak of 87%. In group 2, 27 of the 33 patients (82%) achieved stable donor chimerism 490% within a median of 25 days after transplantation (range 8-103 days); 3 patients (9%) failed to engraft, with donor chimerism never reaching 10%; and 3 patients (9%) had secondary graft failure after donor chimerism had reached 93-97%. Second HSPC transplantation using alternative conditioning regimens was performed in eight patients who had primary or secondary graft failure. In group 1, six patients received second transplantation, with four of them successfully engrafted after the procedure. In group 2, two patients received second transplantation, both with successful engraftment.
Survival and clinical outcomes
Thirty-six patients (69%) are alive at a median of 30.2 month after transplantation (range 15.0-58.2). By KaplanMeier analysis, the 4-year overall survival rate was 68.4% for group 1 (Figure 4a ) and 69.7% for group 2 (Figure 4b) . In group 1, three patients (16%) died from complications related to graft failure, two (10%) died from their underlying diseases and one (5%) died 2 years after the transplantation from a nonmedical cause. In group 2, four patients (12%) died from infections during the transplantation (aspergillus, 2; adenovirus, 1; CMV, 1), one patient (3%) died from complications related to graft failure and five patients (15%) died of progression of their malignancies.
Potential correlation between the treatment dose AUC achieved and the rate of engraftment or survival was analyzed. For the rate of engraftment, there was no difference in the median AUC between the subsets of patients who engrafted or were not engrafted, in either group 1 or group 2 (Figure 4c ). For the rate of survival, the median AUC for the subset in group 1 who did not survive was lower than that for the subset who survived (Figure 4d ; P ¼ 0.05), but there was no difference in group 2.
Modified regimens with a higher target AUC Because of the concern that a low treatment dose AUC might contribute to a poorer clinical outcome, especially in Test dose clearance the younger patients, we modified the conditioning regimens for a second cohort of patients to target the treatment dose AUC at a higher value. Six earlier patients in this cohort had the AUC targeted at 4600-4800 mM min, and seventeen later patients, 5000 mM min (range 4200-5800). The characteristics of the patients are shown in Table 4 . Thirteen patients were less than 4 years of age, and ten patients were older than 4 years. Seventeen of the patients had nonmalignant diseases and six had malignant diseases (immunodeficiency, 2; marrow failure, 2; osteopetrosis, 1; hypereosinophilia, 1; MDS, 1; ALL, 3; AML, 1; CML, 1). PK studies performed after a test dose of 0.8 mg/kg showed that the median test dose AUC achieved was 932 mM min (range 625-1452), with a wide dispersion in the distribution (Figure 5a ). The treatment dose for each patient was individualized according to the modified dose-adjustment protocol. The median treatment dose given was 4.5 mg/kg (range 2.6-6.5), with 22 patients required a dose over 3.2 mg/kg and 1 patient received a dose less than 3.2 mg/kg.
PK studies performed after the first treatment dose revealed that the median treatment dose AUC achieved was 4825 mM min (range 3719-5900), close to the intended AUC of 5000 mM min ( Figure 5b ). As compared with the test dose AUC, the treatment dose AUC showed a reduced dispersion in its distribution, again demonstrating the effectiveness of our dose-adjustment protocol. Over 90% of patients achieved AUC within the higher targeted range of 4200-5800 mM min after dose adjustment (Figure 5c ). There was also improved consistency in the AUC values before and after dose adjustment for individual patients, which might reflect a learning curve in our ability to measure PK values accurately. The median BU clearance for this cohort after the test dose and treatment dose was 3.55 and 3.7 ml/min per kg, respectively (Figure 5d ). Preliminary analysis of the clinical outcome of this cohort was performed. The duration of follow-up was shorter, with a median time of 7.9 months after transplantation (range 2-16.5). Patients experienced only mild nausea and vomiting. No patient had seizure or VOD. Three patients (13%) developed grade 2 and one patient (4%) developed grade 4 acute GVHD. Of the 23 patients, 21 (91%) achieved stable donor chimerism 490% within a median of 18 days (range 11-103). Among these patients, one achieved full donor chimerism at 16 days but developed aplastic anemia at 3 months because of a primary EBV infection. One patient sustained mixed donor chimerism at 50% after initially reaching a maximum of 99%. Two patients (9%) did not engraft, and one of them died from complications related to graft failure. One other patient died from disease progression at 4 months post transplantation. Of the 23, 21 patients (91%) are currently alive at a median of 7.1 months after transplantation (range 2-16.5).
Discussion
In this study, we examined the PK profile of i.v. BU used as a conditioning agent in children receiving RIC SCT. We validated the effectiveness of an individualized BU dosing protocol to achieve a targeted BU exposure, demonstrated an age-dependent difference in the PK profile of single daily dose i.v. BU and determined an appropriate therapeutic range for i.v. BU when used in RIC regimens.
Previous studies have suggested that a standard dose of i.v. BU at 0.8 mg/kg will give an expected AUC of 1000 mM min (range 800-1200). 39 Our results partially confirmed this observation but showed a significant dispersion in the AUC distribution, representing interpatient variability in systemic exposure after administration of i.v. BU. To minimize this variability, we used a test-dose-based individualized dosing strategy, 17 which assumed that the variability arose from intrinsic patient-specific PK differences that could be compensated by dose adjustment. It also assumed that the PK data after a small test dose were predictive of the PK profile after a larger treatment dose was given later, a reflection of dose linearity of the drug.
Our results indicated that these assumptions are correct and the dose-adjustment strategy worked well. In our first cohort of patients, 67% in group 1 and 84% in group 2 achieved AUC within the targeted range after the dose adjustment. In our second cohort, over 90% of the patients achieved the desired AUC. These figures fared well when compared with the results of other strategies to target BU exposure. Using an age-based dosing regimen for i.v. BU given every 6 h, for instance, Booth et al. 34 achieved a desired target exposure in 60% of pediatric patients; Vassal et al. 35 used a multiple-strata, weight-based BU dosing regimen and achieved a desired AUC in 76% of patients; and Tran et al.
12 used therapeutic drug monitoring with subsequent dose adjustments and achieved targeted BU levels in 72% of patients.
An age-dependent pattern in PK profile after i.v. BU was consistently seen in our study. The AUC achieved after a dose of i.v. BU correlated inversely with the weight and age of the patient (Figures 1c and 2c) . Because the BU clearance is defined as the weight-normalized BU dose divided by the AUC achieved, it is then dependent on the age of the patient. Our data showed that BU clearance after a single daily i.v. dose is 4 ml/min per kg in infancy and declines linearly to about 3.5 ml/min per kg at 10 years of age (body weight B40 kg) and 3 ml/min per kg at 20 years (B80 kg) ( Figure 3 ). These estimates are comparable to other published data on the clearance of i.v. BU in children. Tran et al. 12 obtained a BU clearance of 4.49 ml/min per kg for patients younger than 6 years of age and 3.35 ml/min per kg for those older than 6 years; Schechter et al. 41 estimated that BU clearance is 3.8 ml/min per kg in children younger than 4 years versus 3.0 ml/min per kg in those older than 4 years; Nath et al. 42 demonstrated a linear decrease in BU clearance from 4.8 ml/min per kg in infancy to 3.3 ml/min per kg at 10 years and to 2.0 ml/min per kg at 20 years; and Vassal et al. 35 reported a clearance of 3.7 ml/min per kg in early infancy, 4 ml/min per kg at 1 year of age and a linear decline to about 2.3 ml/min per kg in adulthood.
We found that the younger patients have not only a higher BU clearance but also a less predictable PK profile. Several younger patients were found to have a high AUC after the test dose and their treatment i.v. BU dose was adjusted downward accordingly. The final treatment dose AUC in some of these patients, however, ended up being below the targeted range (Figure 2b ; Table 3 ). Hence, the more variable PK profile in the younger patients might have contributed to their lower treatment dose AUC achieved despite the use of the dose-adjustment protocol, which worked well for the older children. The greater inducibility of the enzymes responsible for BU catabolism in the younger children might explain the enhanced clearance of the drug in these patients. 26 A recent study has similarly reported that infants receiving i.v. BU on an every 6-h schedule showed high variability in systemic exposure. 30 Most data on the therapeutic range of BU in HSPC transplantation were derived from studies that used myeloablative conditioning regimens. How to translate those results to the context of RIC transplantation is not obvious. The upper limit of the BU therapeutic range in myeloablative transplantation is usually quoted as a total AUC of 21 600-24 000 mM min (that is, 1350-1500 mM min per dose Â 16 doses) and the lower limit, 14 400-16 000 mM min (900-1000 mM min per dose Â 16 doses). 12, 31, 34, [43] [44] [45] [46] In the RIC regimens used in our study, the upper limits of total AUC were 9600 and 11 600 mM min in the first and second cohorts, respectively, and the lower limit, 6400 and 8400 mM min. The total BU exposure in our patients was only about half of that in patients who received myeloablative conditioning regimens. To understand the significance of this difference, a comparison of the relative toxicities and efficacies associated with the conditioning regimens in our study and other studies will be instructive.
The incidence of regimen-associated toxicities correlates with the upper limit of the BU therapeutic range, and VOD is among the most severe complications associated with BU-containing regimens. The reported incidence of VOD after the use of i.v. BU in myeloablative transplantation is variable, probably related to whether a second alkylating agent is used in the conditioning regimen. Hassan et al. 47 reported a VOD incidence of 11% in pediatric patients who received liposomal BU twice a day for 4 days; Tran et al. 12 reported no cases of VOD in 20 children who received i.v. BU four times a day for 4 days; Zwaveling et al.
18,48 saw a VOD incidence of 26 and 6% after i.v. BU was given either four times or once a day for 4 days; Schechter et al. 41 documented an 18% incidence of VOD after i.v. BU given every 6 h for 4 days; 41 and Bartelink et al. 49 reported a 37% incidence after four once daily doses of i.v. BU. In contrast, in our study of 75 patients who received RIC regimens, none experienced VOD after the use of single daily doses of i.v. BU for 2 days. The incidence of other regimen-related toxicities was also low in our patients. These low incidences support the hypothesis that RIC regimens reduce toxicities. The corollary is that there will be a wide safety margin in the upper limit of BU therapeutic range in our RIC regimens. In other words, the targeted BU therapeutic range in RIC regimens could conceivably be moved upward without causing more regimen-related toxicities.
The rate of graft failure is generally accepted to correlate with the lower limit of the BU therapeutic range, as suggested in studies that utilized 16 doses of oral BU. 31, 46 It was estimated in these studies that there would be a graft failure rate of 10-20% if the steady-state concentration of BU dropped below 600 ng/ml (equivalent to an AUC at B900 mM min after an every 6-h dose). In more recent studies that used i.v. BU as part of a myeloablative conditioning regimen, Tran et al. 12 reported a 10% graft failure rate; Zwaveling et al. 18, 48 reported 10% using four times a day dosing and 22% using once a day dosing; Schechter et al. 41 reported no graft failure in their cohort and Bartelink et al. 49 reported 6%. It was not established in these recent studies whether there is a relationship between the AUC attained and the incidence of graft failure.
In our first cohort of patients, the overall rate of graft failure is relatively high at 31%. In our patients, we also saw an age-dependent difference in the rate of graft failure. In the older age group, 21% of our patients experienced primary or secondary graft failure, whereas in the younger age group, 44% of our patients experienced graft failure. The high rate of graft failure in our younger patients coincided with the low treatment dose AUC they achieved. We could not directly correlate the AUC achieved and the probability of graft failure in individual patients, but the potential connection between the two variables in the younger patients as a group is worrisome. Graft failure in the younger patients could also be a result of other confounding factors. For example, the use of UCB, low donor cell numbers, difference in the underlying diseases and inclusion or exclusion of other conditioning or immunosuppressive agents could all contribute to graft failure. The small number of patients in our study precluded a detailed multivariate analysis, but the possibility that a low AUC contributed to graft failure in our patients was a real concern.
We made use of the wide safety margin in the upper limit of the therapeutic range of i.v. BU in our RIC regimens to address this concern. In the modified protocol, we increased the targeted AUC to 5000 mM min in a second cohort of patients. Over 90% of patients in this cohort achieved an AUC in the higher targeted range after dose adjustment. Concomitant with the achievement of a higher AUC, the engraftment and donor chimerism rates in this cohort also improved to over 90%. There was a corresponding decrease in transplantation-related complications. Although we cannot yet say that the improved clinical outcome is directly related to the higher AUC achieved, our ability to achieve a much-improved engraftment rate after RIC transplantation is promising, and the results need to be confirmed by a longer follow-up of our patients and the study of more patients.
To conclude, our study demonstrates that the use of two single daily doses of i.v. BU, in combination with Flu, is an effective and safe conditioning regimen for pediatric patients undergoing allogeneic HSPC transplantation, if adequate BU exposure can be assured. A test-dose-based individualized i.v. BU dosing protocol helps target the optimal BU exposure and compensate for the variability in the BU PK profile. Nonengraftment is a potential problem in children less than 4 years of age because of their higher and more variable BU clearance. For RIC regimens using i.v. BU, a targeted AUC of 5000 mM min per day for 2 days is recommended for pediatric patients, especially those less than 4 years of age.
